Bisphosphonate Prescribing, Persistence and Cumulative Exposure in Ontario, Canada

DSpace/Manakin Repository

Bisphosphonate Prescribing, Persistence and Cumulative Exposure in Ontario, Canada

Citable link to this page

 

 
Title: Bisphosphonate Prescribing, Persistence and Cumulative Exposure in Ontario, Canada
Author: Burden, A. M.; Paterson, J. M.; Mamdani, M.; Juurlink, D. N.; Cadarette, S. M.; Solomon, Daniel Hal

Note: Order does not necessarily reflect citation order of authors.

Citation: Burden, A. M., J. M. Paterson, D. H. Solomon, M. Mamdani, D. N. Juurlink, and S. M. Cadarette. 2012. Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporosis International 23(3): 1075-1082.
Full Text & Related Files:
Abstract: Summary: We studied new users of oral bisphosphonates and found that less than half persisted with therapy for 2 years, and interruptions in use were common. During a median observation period of 4.7 years, 10% of patients filled only a single prescription, 37% switched therapies and median cumulative exposure was 2.2 years. Introduction: We sought to describe bisphosphonate prescribing, persistence and cumulative exposure among seniors in Ontario, Canada. Methods: We used Ontario Drug Benefit pharmacy claims to identify residents aged \(\geq\) 66 years who initiated oral bisphosphonate therapy between April 1996 and March 2009. The first date of bisphosphonate dispensing was considered the index date. Persistence with therapy was defined as continuous treatment with no interruption exceeding 60 days. We examined persistence with therapy and the number of extended gaps (>60 days) between prescriptions over time periods ranging from 1 to 9 years. We also identified the proportion of patients filling only a single prescription and switching to a different bisphosphonate, and calculated the median days of exposure irrespective of gaps in therapy. Results: A total of 451,113 eligible new bisphosphonate users were identified: mean age = 75.6 years (SD = 6.9), 84% female, and median follow-up length = 4.7 years. Persistence with therapy declined from 63% at 1 year to 46% at 2 years and 12% at 9 years. Among those with at least 5 years of follow-up (n = 213,029), 61% had one or more extended gaps in bisphosphonate therapy. Overall, 10% of patients filled only a single prescription, 37% switched to a different bisphosphonate and the median exposure was 2.2 years. Conclusion: Less than half of patients persisted with bisphosphonate therapy for 2 years and interruptions in therapy were common, with most patients experiencing two or more >60-day gaps in therapy. Interventions are needed to improve persistence with bisphosphonate therapy and reduce the frequency of gaps in treatment.
Published Version: doi:10.1007/s00198-011-1645-7
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277689/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10318189
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters